Isosterix

Isosterix is a preclinical-stage biotechnology company focused on developing highly selective small molecule inhibitors of Carbonic Anhydrase IX (CAIX) and XII (CAXII). These enzymes are primarily expressed in hypoxic tumor environments and play a critical role in pH regulation, which facilitates tumor growth, survival, and metastasis. By targeting these specific isoforms, Isosterix aims to disrupt the metabolic adaptation of cancer cells to hypoxia while minimizing off-target effects on other carbonic anhydrase isoforms. The company's lead programs are designed to treat various solid tumors, particularly those that are resistant to conventional therapies. Isosterix leverages the world-leading expertise of its scientific founders in the field of carbonic anhydrase biology to design its therapeutic candidates. The company is currently advancing its lead candidates through IND-enabling studies to address significant unmet needs in oncology.